Skip Navigation

Newsroom

HHS awards $487 million contract to build first U.S. manufacturing facility for cell-based influenza vaccine

The U.S. Department of Health and Human Services (HHS) today announced a $487 million multiple year contract with Novartis Vaccines and Diagnostics, Inc., to build the first U.S. facility to manufacture cell-based vaccine for seasonal and pandemic flu. More >>

Medical Planning and Countermeasures

 

Learn More >>

In The Spotlight

Operations and Training

Learn More >>

Communicating in a Crisis

Learn More >>

News In Pictures

 

Learn More >>